Compare AU
Compare DRUG vs. XCO2
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are DRUG and XCO2. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | XCO2 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 18 |
Median incremental investment | $967.00 | $820.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,103.93 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | XCO2 | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | XCO2.AX was created on 2022-10-11 by VanEck. The fund's investment portfolio concentrates primarily on theme equity. VanEck Global Carbon Credits ETF (Synthetic) gives investors exposure to the price of carbon as reflected in futures markets |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | VanEck Global Carbon Credits ETF (Synthetic) (100 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.57 % | 0.45 % |
Key Summary
DRUG | XCO2 | |
|---|---|---|
Issuer | BetaShares | VanEck |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | ICE Global Carbon Futures Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.45 % |
Price | $8.12 | $17.95 |
Size | $191.120 million | $2.839 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 1.90 % | 0.45 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/10/2022 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | XCO2 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 18 |
Median incremental investment | $967.00 | $820.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $1,103.93 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | XCO2 | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | XCO2 |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |